Practice
Featured experience
Bristol Myers Squibb $13 billion notes offering
The investment-grade offering comprised nine tranches
Cisco Systems $13.5 billion notes offering
The investment-grade offering comprises seven tranches of notes
Galderma Group CHF2.3 billion ($2.6 billion) IPO
We advised Galderma on its IPO
Novartis $3.7 billion notes offering
We advised Novartis on the investment-grade debt offering
Merck $8 billion notes offering, including its debut sustainability debt
The offering includes five tranches of notes
Nubank $2.6 billion IPO
We advised Nubank on its dual listing on the NYSE and São Paulo Stock Exchange
CANbridge Pharmaceuticals HK$685 million IPO
We advised CANbridge Pharmaceuticals on its IPO and HKEX listing
Avianca $1.05 billion DIP-to-exit financing
We advised an ad hoc group of investors on Avianca’s DIP-to-exit financing
Baker Hughes $1.25 billion notes offering
We advised Baker Hughes on the investment-grade debt offering
Encore Capital $300 million tender offer
The offer was structured as a modified “Dutch Auction” cash tender offer for common stock
Galaxy Digital $500 million exchangeable senior notes offering
We advised Galaxy Digital on its private placement of 3% exchangeable senior notes due 2026
Silvergate Capital $552 million follow-on offering
The shares are listed on the New York Stock Exchange
KKR $750 million senior notes offering
The 3.25% investment-grade notes are due 2051
Marsh McLennan $750 million senior notes offering
We advised Marsh McLennan on its investment-grade debt offering